Abstract: Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

Abstract: A method of using a pharmaceutical composition comprising metronidazole, clotrimazole and chlorhexidine for treating patients suffering from hemorrhoids, is disclosed. The mixture of metronidazole, clotrimazole and chlorhexidine can be applied to contact the hemorrhoids to relieve and/or reduce the symptoms caused by the hemorrhoids. Various application forms including solid forms and solution forms of the mixture of compounds can be used to treat the hemorrhoids.

Abstract: Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

Abstract: Pharmaceutical compositions comprising ebastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from insomnia are also disclosed.

Abstract: Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

Abstract: Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine are disclosed.

Abstract: Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.

Abstract: Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine are disclosed.

Abstract: Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine are disclosed.

Abstract: Pharmaceutical compositions comprising ebastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from insomnia are also disclosed.

Abstract: Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.

Abstract: A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and donepezil or rivastigmine or galantamine or a pharmaceutically acceptable salt of thereof is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.

Abstract: Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and folic acid or folate, and/or salts, metabolites, or derivatives thereof are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders or symptoms, such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.

Abstract: Pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt of azelastine, and methylcobalamin are disclosed. Methods of using the pharmaceutical compositions for treating patients with Alzheimer's disease or Parkinson's disease are also disclosed.

Abstract: Pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt of azelastine, and methylcobalamin are disclosed. Methods of using the pharmaceutical compositions for treating patients with Alzheimer's disease or Parkinson's disease are also disclosed.

Abstract: Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine are disclosed.

Abstract: Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine are disclosed.

Abstract: A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and memantine or a pharmaceutically acceptable salt of memantine is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.

Abstract: A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and memantine or a pharmaceutically acceptable salt of memantine is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.

Abstract: Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating perimenopausal or menopausal patients, such as patients suffering from, experiencing, exhibiting and/or having one or more symptoms of anxiety or depression, are also disclosed.